Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupAcute LeukemiasNeuro-OncologyDiseaseAcute Lymphoblastic LeukaemiaMalignant MeningitisSubgroupLeukemic MeningitisICD10C79.3C91.0-MeSHMeningeal CarcinomatosisPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaSequenceChemotherapyChemo-substanceCytarabineDexamethasoneMethotrexateChemo-substanceCytarabineDexamethasoneMethotrexateChemo-substanceCytarabineDexamethasoneMethotrexateChemo-substanceCytarabineDexamethasoneMethotrexateNo. Substances123 RadiotherapySupportive therapySupportive substanceFolinic acidSupportive substanceFolinic acidSupportive substanceFolinic acidSupportive substanceFolinic acidNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseTherapy intentioncurativeRisksEmetogenicityEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorGökbuget NKopmar NRausch CDiseaseAkute lymphatische Leukämie, B/T lymphoblastisches LymphomHochmaligne B-ALL/T-ALL und Burkitt-Lymphom bei Erwachsenen, ErstlinieOriginDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TexasGerman Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, GMALL 07/2003Protocols in Revision 3 protocols foundProtocols under revision.Cytarabine 40 / Dexamethasone 4 / Methotrexate 15, intrathecal, CNS Prophylaxis, Malignant Meningitis (PID602 V2.0)Methotrexate 12 / Cytarabine 100, Malignant Meningitis, CNS Prophylaxis (PID2575 V1.0)Methotrexate 15, Malignant Meningitis, CNS Prophylaxis (PID876 V1.1)
